New GLP-1 Pens in Brazil: A Practical Checklist Before Your First Prescription

If you have type 2 diabetes or obesity, you've probably heard that new GLP-1 pens are reaching Brazil. This checklist walks you through what to verify before your first prescription, from confirming a product with Anvisa to setting up storage at home. It can help you arrive at the appointment prepared, but it does not replace your doctor.

Approval Is Not the Same as Being Right for You

Four ideas get mixed up all the time: registration, prescription, coverage, and clinical fit. Anvisa, Brazil's health regulator, reviews and registers medicines. A registration tells you a product is legally approved. It doesn't tell you whether that product suits you.

A prescription is your doctor's decision. Coverage is what your health plan or the public system will pay for. Clinical fit depends on your history, your other medications, and your goals. A registered pen can still be a poor match for someone with certain conditions.

Also note the difference between a registered medicine (registro) and a compounded preparation (manipulação). Registered products have passed Anvisa's review as finished medicines. Compounded versions follow different rules, so they are not interchangeable.

How to Check the Registration Yourself

Start with Anvisa's public medication consultation portal at consultas.anvisa.gov.br. You can search by commercial name, active ingredient, or registration number. Searching by active ingredient, such as tirzepatide, shows every registered product that contains it.

Next, compare what the portal shows with your box and leaflet (bula). The registration number should match. Check the commercial name, the holder company, and the manufacturer or importer listed. Then confirm the presentation: pen type, dose strengths, and pens per box.

Strengths and presentations can change, so trust the current leaflet over any older summary, including one you found online. If anything doesn't match, stop and ask your pharmacy or doctor before buying or using the pen. For more background, browse MounjaBlog's home page, but the official leaflet always comes first.

Questions to Bring to the Appointment

Your medical history can change the decision. Tell your doctor about any personal or family history of medullary thyroid carcinoma or MEN2, a rare genetic syndrome. The tirzepatide leaflet, which you can read in Anvisa's bulário, gives thyroid C-cell tumors a boxed warning and lists these conditions as reasons the medicine should not be used.

Also mention past pancreatitis, gallbladder disease, diabetic eye complications, and kidney problems. The leaflet includes warnings about several of these, so your doctor needs the full picture.

Bring a complete list of current medications, supplements included. Insulin and sulfonylureas deserve special attention because they can lower blood sugar on their own. Adding a GLP-1 pen can increase that risk. Your doctor may adjust those doses, so don't change them yourself.

Ask about contraception too. The leaflet discusses oral hormonal contraceptives and says you need guidance on using them with the medicine. Ask whether your current method still works for you.

Print these questions and bring them along:

• What starting dose do you recommend, and how and when will we adjust it?
• When will you review how I'm doing?
• What can I do if nausea makes it hard to eat or drink?
• What results are realistic for my health and goals?

The Cost and Coverage Questions Nobody Warns You About

There are three paths to getting the medicine. You can buy it out of pocket, use a private health plan (plano de saúde), or check whether the public system (SUS) offers it. Each path works differently, so don't assume one answer covers all three.

SUS availability depends on Conitec's evaluations, and those can change. Before you plan around it, check Conitec's most recent decision and its date. Don't rely on what a friend or a forum says.

Ask your doctor to write the prescription with both the generic name and the brand name. That helps the pharmacy and your insurer match the right product.

Private plans follow rules set by ANS, the regulator for health plans, including its reference list of procedures. Coverage for a medicine you use at home still depends on your contract. Ask whether your plan requires prior authorization, and get the answer in writing.

Coverage can be denied. If that happens, our coverage denial post explains the next steps. Keep a folder, paper or digital, with the prescription, every invoice, and all correspondence from your insurer. If you need to appeal, those records do most of the work. Our coverage guides have more on organizing this paperwork.

Setting Up Your First Week at Home

Keep unused pens in the refrigerator, never in the freezer, and leave them in the original box to protect them from light. Follow the temperature range printed in your leaflet, and don't guess.

Once you open a pen, the rules change. The leaflet sets an in-use time limit and storage temperature. Write the start date on the box or in your phone, and check it before each dose. Don't use the pen past that limit, even if it looks fine.

Inspect the pen before every dose. The liquid should look clear and colorless, the dose counter should show the setting you expect, and the needle should attach securely. If the liquid looks cloudy, discolored, or has particles, don't inject it. Call your pharmacy or care team instead.

A written routine makes these checks easier to repeat. Many readers keep one, like the MounjaBlog pen routine, so the steps stay consistent from week to week.

If you miss a dose, follow the window in the leaflet and ask your care team before doubling up. Dispose of needles right after use in a rigid, puncture-resistant sharps container. Never recap a needle or toss loose needles into household trash. Check your local collection rules, and consult the Ministry of Health's guidance when you're unsure.

What to Watch for and When to Call a Doctor

Nausea, diarrhea, constipation, and reduced appetite are common side effects, especially after a dose increase. Tell your care team if they linger or keep you from eating or drinking.

Some symptoms need prompt care. Severe or persistent abdominal pain can point to pancreatitis. Pain under the right ribs or yellowing skin can signal gallbladder trouble. Vision changes, swelling of the face or throat, and signs of a serious allergic reaction also need urgent attention.

In an emergency, call your local emergency number or go to the nearest emergency room. Don't wait for an appointment.

Vomiting and diarrhea can cause dehydration, and dehydration can strain your kidneys. Watch for dark urine, dizziness, or passing very little urine. If these symptoms persist, contact your care team rather than waiting them out.

Low blood sugar is more likely if you also take insulin or sulfonylureas. Watch for shakiness, sweating, a racing heart, confusion, or unusual hunger. Treat it as your doctor instructed, and report every episode.

Finally, keep a short log of doses, symptoms, meals, and questions for your next visit. Those notes give your doctor real information to work with, not guesses from memory.

Your doctor makes the final prescribing decision, so treat this checklist as preparation, not permission. Print it, fill it in, and bring it to your next appointment. A MounjaBlog checklist in hand can make that conversation more focused.

FAQ

Is a registered GLP-1 pen the same as a compounded one?

No. A registered medicine has passed Anvisa's review as a finished product. A compounded preparation is made by a pharmacy under different rules, so the two aren't interchangeable.

Can I check Anvisa registration without a prescription?

Yes. Anvisa's consultation portal lets you search by commercial name, active ingredient, or registration number. Compare what you find with the box and the leaflet.

What if I miss a dose?

Follow the missed-dose window written in your leaflet, and ask your care team before taking extra medicine to catch up.

Do I need to tell my doctor about my birth control?

Yes. The leaflet discusses oral hormonal contraceptives and says you need guidance on using them, so raise it directly with your doctor.

Sources

• Anvisa - Consulta de medicamentos e bulário eletrônico
• Anvisa - Agência Nacional de Vigilância Sanitária
• ANS - Agência Nacional de Saúde Suplementar
• Conitec - Comissão Nacional de Incorporação de Tecnologias no SUS
• Ministério da Saúde